Search

Displaying results 391 - 400 of 7555 in total
  1. Indication

    Cutaneous T-Cell Lymphoma (CTCL)

    go.drugbank.com/conditions/DBCOND0071861
    Drugs: Cladribine · Gemcitabine · Interferon alfa-2a · Methoxsalen · Pralatrexate · Romidepsin
    Synonyms: Cutaneous T-cell lymphoma, no ICD-O subtype, Cutaneous T-cell lymphoma, no International Classification of Diseases for Oncology subtype
  2. Indication

    Oligodendroglioma

    go.drugbank.com/conditions/DBCOND0002896
    Drugs: Procarbazine
    Synonyms: Oligodendroglioma, no International Classification of Diseases for Oncology subtype
  3. Drug

    Cetylpyridinium

    go.drugbank.com/drugs/DB11073
    ApprovedInvestigational

    Cetylpyridinium is a quaternary ammonium with broad-spectrum antiseptic properties. Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, ...

    Mixtures: BUCOSEPTOL N, Emercreme No4 Ont EfaProducts: NEO FORMITROL, NEO CORICIDIN GOLA
  4. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. … Sitagliptin was granted FDA approval on October 16, 2006[L6061].

    Mixtures: Nb-sitagliptin-metformin, Nb-sitagliptin-metforminProducts: Nb-sitagliptin
  5. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. … Ticagrelor was granted EMA approval on 3 December 2010.[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]

    Products: Na
  6. Drug

    Desmopressin

    go.drugbank.com/drugs/DB00035
    ApprovedInvestigational

    It is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … Additionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458

    Products: Nu-desmopressin Spray
  7. Drug

    Alendronic acid

    go.drugbank.com/drugs/DB00630
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

    Mixtures: ALENDRON-HEXAL 4 WO CAL D, ALENDRON-HEXAL 12 WO CAL DProducts: Nb-alendronate-FC
  8. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market due to

    Products: MERBROMINA NA
  9. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    [A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort. … Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight.

    Mixtures: Pepto-Bismol and Pepto-Bismol To Go, Pepto-Bismol and Pepto-Bismol To GoProducts: NEO ADIAR, Upset Stomach Relief to Go
  10. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … Although pidolic acid is included in some over-the-counter, non-prescription dietary supplements for the proposed purpose of facilitating cognitive or memory enhancement, most available research suggest